This Diet Reduces Dementia Risk, Scientists Say
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
With dementia diagnoses on the rise as the U.S. population grows older, many people are wondering what they can do to protect their brain health. A new study points to a surprisingly simple answer: your diet.
Researchers found that sticking to the MIND diet—a hybrid of the Mediterranean and DASH (Dietary Approaches to Stop Hypertension) diets—were significantly less likely to develop Alzheimer's disease and related dementias.
"Our study findings confirm that healthy dietary patterns in mid-to-late life and their improvement over time may prevent Alzheimer's and related dementias," said paper author professor Song-Yi Park of the University of Hawaii at Manoa.
"This suggests that it is never too late to adopt a healthy diet to prevent dementia."
An estimated 7.2 million Americans age 65 and older are living with Alzheimer's dementia in 2025, according to the Alzheimer's Association. But researchers have found that following this diet over ten years can reduce the risk by 25 percent.
A stock image of a senior man eating a salad.
A stock image of a senior man eating a salad.
Miljan Živković/iStock / Getty Images Plus
What is the MIND Diet?
The MIND diet combines two powerful eating plans: the Mediterranean diet—known for its links to heart health and longer life—and the DASH diet, originally created to help reduce high blood pressure. MIND stands for Mediterranean–DASH Intervention for Neurodegenerative Delay.
This brain-focused diet emphasizes whole grains, leafy greens, berries, beans and nuts. It also encourages moderate intake of other vegetables, fish, seafood, poultry and olive oil. At the same time, it recommends limiting red meat, wine, fast food, fried foods, butter, margarine, pastries and sweets like candy.
A stock image of food products representing the MIND diet created to reduce dementia and the decline in brain health.
A stock image of food products representing the MIND diet created to reduce dementia and the decline in brain health.
monticelllo/iStock / Getty Images Plus
The Study
The study analyzed data from nearly 93,000 U.S. adults as part of the Multiethnic Cohort Study. Participants, aged 45–75 at the start of the study in the 1990s, shared their dietary habits, and more than 21,000 went on to develop Alzheimer's or related conditions in the decades that followed.
According to the study, those who followed the diet most closely had a nine percent lower risk of developing dementia overall. The effect was even more pronounced—around 13 percent—among African American, Latino and White participants.
"We found that the protective relationship between a healthy diet and dementia was more pronounced among African Americans, Latinos and Whites, while it was not as apparent among Asian Americans and showed a weaker trend in Native Hawaiians," Park noted. "A tailored approach may be needed when evaluating different subpopulations' diet quality."
Significantly, the study also revealed that individuals who improved their adherence to the MIND diet over time experienced a 25 percent lower risk of dementia compared to those whose adherence declined. This trend held true across age and racial groups, reinforcing the potential benefits of making dietary changes at any point in life.
Researchers pointed out that cultural differences in dietary preferences may influence how effective the MIND diet is for different groups.
While Asian Americans generally have lower rates of dementia, their traditional diets may offer protective benefits not captured by the MIND framework. Park emphasized the need for future interventional research to confirm these observational findings and to explore more culturally adapted dietary approaches.
Do you have a tip on a health story that Newsweek should be covering? Do you have a question about dementia? Let us know via health@newsweek.com.
Reference
Park, S.-Y., Setiawan, V. W., Crimmins, E., White, L., Haiman, C., Wilkens, L. R., Marchand, L. L., & Lim, U. (2025). The MIND Diet and Incidence of Alzheimer's Disease and Related Dementias Among Five Racial and Ethnic Groups in the Multiethnic Cohort Study. NUTRITION 2025, Orlando, Florida.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
an hour ago
- Newsweek
Jordan Peterson Diagnosed With Chronic Condition After Exposure to Mold
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Jordan Peterson has been diagnosed with a chronic immune system dysfunction condition after being "exposed to a particularly moldy environment," his daughter has said. Mikhaila Peterson said in a post on X that her father has chronic inflammatory response syndrome (CIRS) " due to a genetic predisposition that causes the immune system to have an inability to identify and detoxify mold/bacteria in indoor air." Hey guys, @jordanbpeterson is taking some time off of everything. He was diagnosed with CIRS (chronic inflammatory response syndrome) due to a genetic predisposition that causes the immune system to have an inability to identify and detoxify mold/bacteria in indoor air (the… — Mikhaila Peterson (@MikhailaFuller) August 13, 2025 She said that Jordan Peterson had been experiencing "severely flared symptoms" after being exposed to mold while cleaning out her grandfather's house after he passed away. "To be crystal clear - this isn't about akathisia or medication," she said. "He's not on any medication. It's an immune system dysfunction." "CIRS (chronic inflammatory response syndrome) is what has been behind his multiple health issues and random severe allergies and severe food sensitivities over the years," Mikhaila Peterson continued. "He's really been suffering from this badly since 2017 we just didn't know what it was called. Only eating meat helped keep the symptoms under control but it hasn't been enough recently." This is a developing story - more to follow.
Newsweek
3 hours ago
- Newsweek
Another State Looks To Ban Junk Food From SNAP Benefits
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Mississippi Governor Tate Reeves has said his state may block the purchase of unhealthy foods using SNAP benefits. Newsweek has contacted Reeves' office for comment via email outside regular working hours. Why It Matters So far in 2025, a slew of states have either barred or are in the process of restricting what Supplemental Nutrition Assistance Program (SNAP) beneficiaries can buy using their benefits. Advocates for restricting SNAP purchases argue that cutting unhealthy foods from the program will improve public health, with the Make America Healthy Again (MAHA) movement leading the charge. Opponents counter that such limits dictate the diets of low-income Americans while overlooking deeper problems related to accessing affordable, nutritious food. According to the Center on Budget and Policy Priorities, in Mississippi, some 384,800 people collect SNAP benefits, representing 13 percent of the state's population. What To Know Reeves, a Republican, said of restricting SNAP benefits, "It is on my radar," SuperTalk Mississippi Media reported on Wednesday. According to the outlet, he also discussed the idea with Health and Human Services Secretary Secretary Robert F. Kennedy Jr., who has spearheaded the MAHA movement, at the National Governors Association summer meeting. "I spent some time with my fellow governors a week or two ago," Reeves said. "We also had meetings with Secretary Kennedy while we were at the conference, very productive meetings, and that is something we are looking into." Republican Governor Tate Reeves speaks with supporters during an election night watch party at the Refuge Hotel & Conference Center in Flowood, Mississippi, on November 7, 2023. Republican Governor Tate Reeves speaks with supporters during an election night watch party at the Refuge Hotel & Conference Center in Flowood, Mississippi, on November 7, 2023. Brandon Bell/GETTY SNAP Changes Across the U.S. So far this year, 12 states have approved plans to restrict SNAP benefits. While the program is administered by states, it is overseen and largely paid for by the U.S. Department of Agriculture (USDA). To make amendments to SNAP, states are required to send waiver requests to the federal agency for approval. Arkansas, Colorado, Florida, Idaho, Indiana, Iowa, Louisiana, Nebraska, Oklahoma, Texas, Utah and West Virginia have all had their waiver requests approved. Tennessee and South Carolina have indicated that they are in the process of making similar requests to the USDA. Beginning in 2026, the approved waivers are set to prohibit certain foods from being purchased with electronic benefit transfer cards, which are reloaded monthly for use at participating grocery stores nationwide. Not all the new restrictions are the same. For example, in Colorado, Utah and West Virginia, only soft drinks and/or soda would no longer be purchasable with SNAP. In numerous other states, the restriction also extends to candy. What People Are Saying USDA Secretary Brooke Rollins said in an August 4 news release regarding states with approved waivers: "It is incredible to see so many states take action at this critical moment in our nation's history and do something to begin to address chronic health problems. President Trump has changed the status quo, and the entire cabinet is taking action to Make America Healthy Again. At USDA, we play a key role in supporting Americans who fall on hard times, and that commitment does not change. Rather, these state waivers promote healthier options for families in need." Health and Human Services Secretary Robert F. Kennedy Jr. said in the news release: "For years, SNAP has used taxpayer dollars to fund soda and candy—products that fuel America's diabetes and chronic disease epidemics. These waivers help put real food back at the center of the program and empower states to lead the charge in protecting public health. I thank these governors who have stepped up to request waivers, and I encourage others to follow their lead. This is how we Make America Healthy Again." Valerie Imbruce, the director of the Center for Environment and Society at Washington College, previously told Newsweek: "Controlling how the poor eat is a paternalistic response to a problem that is not based in SNAP recipients' inability to make good decisions about healthy foods, it is a problem of the price differential in choosing healthy or junk foods. Soda and candy are much cheaper and more calorie dense than 100 percent fruit juices or prebiotic non-artificially sweetened carbonated beverages, thanks to price supports and subsidies by the federal government to support a U.S. sugar industry." What Happens Next Reeves' comments suggest that Mississippi has not formally requested a waiver from the USDA. It remains to be seen whether the state will do so.
Yahoo
15 hours ago
- Yahoo
Alzheimer's disease market to reach $17bn across 8MM by 2033
The Alzheimer's disease market is expected to grow at a high compound annual growth rate (CAGR) of 21.8% from $2.4bn in 2023 to $17bn by 2033 across the eight major markets (8MM: the China, France, Germany, Japan, Italy, Spain, the UK and the US), according to GlobalData's recent report, Alzheimer's Disease: Eight-Market Drug Forecast and Market Analysis - Update. The major driving factors of this growth include the ageing global population, which will lead to an increase in prevalent cases, the entry of expensive disease-modifying therapies (DMTs) into the market, which will likely result in increased treatment rates as more options become available, and the launch of novel symptomatic therapies including the first US Food and Drug Administration (FDA)-approved therapies for the treatment of agitation and psychosis associated with Alzheimer's. A major focus of research and development in the Alzheimer's therapeutic space is preventing the accumulation of amyloid beta (Aβ). Despite many historical failures, this strategy has come to fruition for drug developers in recent years with the entry of the first DMTs to the market. The FDA approved Eisai/Biogen's Leqembi (lecanemab) in January 2023 and Lilly's Kisunla (donanemab) in July 2024, and both drugs have since been approved in Japan, China and the UK. In April 2025, after multiple delays, the European Medicines Agency approved Leqembi in a restricted population compared with the US, preventing it from being prescribed to patients who are APOE4 homozygotes [individuals who have inherited two copies of the APOE4 gene variant, one from each parent, increasing their likelihood of developing the disease]. Although the approval of the first DMTs for the treatment of Alzheimer's is a significant step forward, a key limiting factor in their uptake has been their integration into clinical practice so that they can be widely available for patients. Frequent intravenous (IV) administration places a high burden on care settings in which the drug can be administered, and access to positron emission tomography and magnetic resonance imaging (MRI) scans is a key economic and operational limiting factor for access to these drugs. In addition to logistical factors, these new DMTs are significantly more expensive than the current highly genericised symptomatic treatments used in the management of Alzheimer's, providing a further access challenge in the form of reimbursement/payer restrictions. Indeed, the Japanese Central Social Insurance Medical Council (Chuikyo) recently approved the cost-effectiveness assessment results for Leqembi, recommending a 15% price reduction, with the price change expected to come into effect from 1 November 2025. The final reimbursement guidance for Leqembi and Kisunla in the UK, published in June 2025 following two previous rejections, is that neither drug is recommended for use on the NHS. Developers are investigating alternative routes of administration so that patients will not require multiple lengthy IV infusions to be treated. Eisai and Biogen are currently evaluating a subcutaneous formulation of Leqembi, and Eli Lilly is developing a second anti-Aβ monoclonal antibody (mAb), remternetug, which can also be administered subcutaneously. Additionally, there are several oral late-stage pipeline products with a variety of mechanisms of action that, if approved, should be easier to integrate into clinical practice and therefore be more widely accessible for patients. In clinical trials, these oral products have not been associated with amyloid-related imaging abnormalities, the key side effect associated with the anti-Aβ mAbs that requires MRI monitoring, which would further improve access to these drugs. Overall, DMTs are expected to dominate the global Alzheimer's market, contributing 69.2% of the market by 2033, with drugs targeting Aβ making up the majority of this. GlobalData forecasts that Leqembi and Kisunla could generate global sales of approximately $2.9 billion and $2.3 billion, respectively, by 2033. While the market is projected to experience strong growth throughout the forecast period across the 8MM, unmet needs beyond access to treatment will remain. The rates of diagnosis and treatment are low across all stages of the disease, so there is an unmet need for accurate, easy-to-use diagnostic tests, and for biomarkers that can be used for patient classification and the assessment of treatment response. While blood-based biomarkers are now being used fairly routinely in clinical trials and research, they have not yet entered routine clinical practice, although advances are being made with the first FDA approval of a blood test for diagnosis, Fujirebio's Lumipulse G pTau 217/ß-Amyloid 1-42 Plasma Ratio, in May 2025. Additionally, the new DMTs are only considered to be moderately effective, so a significant opportunity remains for more effective DMTs that do not just slow progression but also stop the disease, with prevention the end goal. Beyond DMTs, drugs that can effectively improve cognition in the late stages of disease, as well as more effective options for secondary symptoms such as agitation and psychosis, also provide an opportunity for developers. Key opinion leaders interviewed by GlobalData did not believe there will ever be one product that could cure Alzheimer's. Rather, they consistently noted that the future of treatment will entail the combinatory use of preventative, symptomatic and disease-modifying products. Despite the significant anticipated growth of the market, activity remains high and there will be many opportunities for developers. "Alzheimer's disease market to reach $17bn across 8MM by 2033" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
